US3676557A - Long-acting narcotic antagonist formulations - Google Patents

Long-acting narcotic antagonist formulations Download PDF

Info

Publication number
US3676557A
US3676557A US3676557DA US3676557A US 3676557 A US3676557 A US 3676557A US 3676557D A US3676557D A US 3676557DA US 3676557 A US3676557 A US 3676557A
Authority
US
United States
Prior art keywords
pamoate
naloxone
oil
di
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
Inventor
Leon Lachman
Roy H Reiner
Elie Shami
Walter Spector
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ENDO LAB Inc
E I du Pont de Nemours and Co
Original Assignee
ENDO LAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ENDO LAB filed Critical ENDO LAB
Priority to US12033671A priority Critical
Application granted granted Critical
Publication of US3676557A publication Critical patent/US3676557A/en
Assigned to E.I. DU PONT DE NEMOURS AND COMPANY reassignment E.I. DU PONT DE NEMOURS AND COMPANY ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: ENDO LABORATORIES, INC., A CORP. OF DEL.
Anticipated expiration legal-status Critical
Application status is Expired - Lifetime legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

The pamoate salts of N-(cyclopropylmethyl)-7,8-dihydro-14hydroxynormorphinone and N-allyl-7,8-dihydro-14hydroxynormorphinone, in oil suspension, are injectable, longacting forms of these narcotic antagonists.

Description

United States Patent Lachman et al.

[ 51 July 11,1972

[54] LONG-ACTING NARCOTIC ANTAGONIST FORMULATIONS Hempstead; Walter Specter, Valley Stream, all of NY.

[73] Assignee: Endo Laboratories, Inc., Garden City,

[22] Filed: March 2, 1971 [21] Appl.No.: 120,336

Related U.S. Application Data [63] Continuation-impart of Ser. No. 56,975, July 21,

1970, abandoned.

[$2] U.S. Cl. ..424/260 [5 1] Int. Cl. ..A6lk 27/12 [58] Field of Search ..424/244, 260

[56] References Cited UNITED STATES PATENTS 3,254,088 5/1966 Lowenstein ..260/285 3,332,950 7/ l 967 3,326,896 6/1967 2,964,448 12/1960 2,507,193 5/ 1950 Buckwalter ..424/271 FOREIGN PATIEN'I'S OR APPLICATIONS 1,461,407 12/1966 France 6,706,464 6/1968 South Africa OTHER PUBLICATIONS Thompson, Am. J. Trop. Med. Hyg. 12, 481 (1963) McGregor, Brit. Med. .1. 695, Mar. 19, 1966 Coatney, Am. J. Trop. Med. Hyg. 12, 504 1963) Waltz, Science, 141 723, Aug. 1963 Blumberg et al ..260/285 Primary ExaminerShep K. Rose AuomeyDon M. Kerr [57] ABSTRACT The pamoate salts of N-(cyclopropylmethyl)-7,8-dihydro-14- hydroxynormorphinone and N-allyl-7,8-dihydro-l4-hydroxynormorphinone, in oil suspension, are injectable, long-acting forms of these narcotic antagonists.

3 Claims, No Drawings LONG-ACTING NARCOTIC ANTAGONIST FORMULATIONS RELATED APPLICATIONS This application is a continuation-in-part of application Ser. No. 56,975, filed July 21, 1970 now abandoned.

BACKGROUND OF THE INVENTION This invention relates to the known narcotic antagonists, N- allyl-7,8-dihydro-l4-hydroxynormorphinone and N- (cyclopropylmethyl)-7,8-dihydro-l4-hydroxynormorphinone. The former compound will sometimes be referred to hereinafter by its generic name, naloxone.

Naloxone and certain of its salts are disclosed in US. Pat. No. 3,254,088 as potent narcotic antagonists. A report by Fink et al., Naloxone in Heroin Dependence," Clinical Pharmacology and Therapeutics, Vol. 9, No. 5, pp. 568-577 (1968) confirms that naloxone is a highly potent antagonist which is relatively free of adverse side, effects. Fink et al. note however that the antagonist action of naloxone is quite brief, and conclude:

The short duration of action may be a serious limitation. Further trials of the narcotic antagonist treatment model are necessary, and naloxone is the best drug available for such studies, but pharmaceutical ingenuity may create compounds with longer durations of action and equal potency and safety.

N-(cyclopropylmethyl)-7,8-dihydro-l4-hydroxynormorphinone and certain of its salts are disclosed in U.S. Pat. No. 3,332,950. This compound is also a potent narcotic antagonist but, like naloxone it suffers the disadvantage of relatively short duration of action.

SUMMARY OF THE INVENTlON DESCRIPTION OF THE INVENTION Di-naloxone pamoate is an odorless, light yellowish-tan powder with the empirical formula (C,,,H ,NO,,) -C H ,O,

and the structural fonnula:

. C OOH CH -CH=CH: I l OH HO I H2 OH H!) 2 COOH Di-naloxone pamoate is prepared by mixing naloxone hydrochloride with disodium pamoate in a 2:1 molar ratio in aqueous solution. The relatively insoluble di-naloxone pamoate precipitates, is removed by filtration, purified by recrystallization from ethanol or other suitable solvent, and dried. The product need not be anhydrous. it will ordinarily contain at least 1 mole of water and may contain up to about 10 percent by weight of combined or uncombined water and/or combined or uncombined solvent. A specific procedure which can be used to produce di-naloxone pamoate is as follows:

To a solution of 9.6 g. (0.024 mol) of naloxone hydrochloride monohydrate in approximately l00.ml. water a solution of 5.4 g. (0.012 mol) of disodium pamoate monohydrate in a similar volume of water is slowly added, with stirring. The precipitate, which forms almost instantaneously, is stirred for about 1 hour, the solvent is filtered off, and the residue washed with water and then dried. Yield: 12 g'.

Recrystallization from 300 ml. of boiling ethanol yields 8 g. of product, which, after drying for 3 hours at in a vacuum oven, decomposes at l98225 C.

Di-[N-(cyclopropylmethyl)-7,8-dihydro-14-hydroxynormorphinone] pamoate is an odorless, buff-colored powder with the empirical formula (C ,,H ',NO,,) -C.,, -,H ,0 and the structural formula: I

: coon r l N OH OH: HO I Hi) 0 2 COOH Di-[N-(cyclopropylmethyl)-7,S-dihydro-14-hydroxynormorphinone] pamoate is prepared in a manner similar to that used for preparing di-naloxone pamoate, and like di-naloxone pamoate it may contain up to about 10 percent by weight of combined or uncombined water and/or solvent. A specific procedure which can be used to produce this salt is as follows:

To a solution of 5.7 g. (0.015 mol) of N-(cyclopropylmethyl )-7,8-dihydro- 1 4hydroxynormorphinone hydrochloride in approximately 100 ml. water a solution of 3.4 g. (0.0075 mol) of disodium pamoate monohydrate in a similar volume of water is slowly added, with stirring. The precipitate which fonns is stirred for about an hour, filtered, and the residue washed with water and dried. Yield: 7.2 g.

Recrystallization from ethanol yields 6.1 g. in two crops, which are combined and dried for 3 hours at 100 C. in a vacuum oven to give material which decomposes at 200-207 C.

The oil medium for suspensions of this invention can be any vegetable oil which is suitable for parenteral use. The vegetable oil, for example, may be peanut oil, corn oil, sesame oil, or cottonseed oil.

ln order to provide stable suspensions, a viscosity-increasing agent is incorporated into the vegetable oil. Suitable viscosityincreasing agents are the fatty acid salts of aluminum, especially those containing about seven to 25 carbon atoms. Aluminum monostearate is particularly preferred. The aluminum monostearate or other viscosity-increasing agent will ordinarily be used in an amount in the range of from 01-50 percent (w/v), based on the oil. The preferred range is 1.0-4.0 percent (w/v).

The viscosity-increasing agent is incorporated into the vegetable oil with agitation and heating as necessary to produce a stable vegetable oil gel. For example, an aluminum monostearate gel can be prepared by suspending an amount of aluminum monostearate in a suitable vegetable oil. Under constant agitation, heat is applied until a temperature of 85-90 C. is attained. A heating rate of 5 C. per minute is applied until this temperature is reached. This temperature is maintained for 30-45 minutes to eliminate water from the system. Heating is continued, but retarded to 23 C. per minute until a temperature of C. is attained. 15 minutes stirring at this temperature will stabilize the gel that is formed. Using this technique, vegetable oil gels can be made at temperatures between 125C. and C.

A preservative can be added to the vegetable oil gel, if desired, in an amount ordinarily used in injectable dosage forms, i.e. about 0.05 percent to 0.5 percent (w/v) based on oil. The parabens, in combinations ordinarily used in parenterals, are preferred, but other preservatives recognized for use in parenterals (e.g. phenol, cresol, chlorobutanol) can also be used.

Antioxidants commonly used in pharmaceutical products may also be incorporated. These include, for example, ascorbyl palmitate, hydroquinone, propyl gallate, nordihydroguaiaretic acid, butylated hydroxy toluene, butylated hydroxy anisole, a-tocopherol and its esters, phenyl anaphthylamine, lecithin, and mixtures of these. The amount of antioxidant, when used, will ordinarily be in the range from about 0.005 to 0.2 percent (w/v) based on the oil.

The suspensions of the invention can also contain other therapeutically active compounds, in amounts sufficient to enhance the utility of the formulation for its intended purpose. These adjuvants can be formulated so as to be released immediately or over an extended period of time. Examples of other types of therapeutically active ingredients which can be included in the suspensions, either as the compounds themselves or their pharmaceutically acceptable salts, are:

a. major tranquilizers, such as chlorpromazine or molindone, or minor tranquilizers, such as chlordiazepoxide, glutethimide or pentobarbital, for the symptomatic relief of narcotic withdrawal symptoms;

b. analeptics, such as picrotoxin or pentamethylenetetrazole, or central nervous system stimulants such as methylphenidate, for antagonism of acute respiratory depression caused by agents other than narcotics; and

0. various narcotics or other narcotic antagonists such as methadone, meperidine or cyclazocine, in dosage ratios which provide retention of analgesia or appropriate withdrawal therapy, while simultaneously minimizing side effects.

ln preparing the suspensions of the invention the di-naloxone pamoate or di-[N-(cyclopropylmethyl)-7,8-dihydro-l4- hydroxynormorphinone] pamoate is added to the vegetable oil gel in amounts equivalent to naloxone hydrochloride or N- cycloproylmethyl-7,8-dihydro-l4-hydroxynormorphinone hydrochloride (anhydrous basis) in the range from about 1 to about 500 mg./ml. of suspension, preferably 2 to 200 mg./ml., more preferably to 100 mg./ml. The mixture is then mechanically worked to reduce the particle size of the suspended materials and thoroughly disperse them in the gel. The average particle size of the suspended materials should be sufficiently small that the suspension is syringeable through a 20 gauge needle. It is preferred that the average particle size be between 5 and 50 microns, and that essentially all of the particles be less than about 100 microns. Particle size reduction and dispersion of the suspended materials can be accomplished with the use of a laboratory blender, colloid mill, sonic mill, or other comparable equipment.

Aseptic techniques may be used throughout the preparation, or other suitable techniques for making sterile parenterals can be used.

A suspension of the invention, containing an amount of dinaloxone pamoate equivalent to mg. of naloxone hydrochloride per ml. in 2 percent aluminum monostearate in peanut oil, was tested for duration of Numorphan-antagonist effect in mice. The test used was the subcutaneous counteraction of the Numorphan HCl induced Straub tail in mice. Two tests, each using three mice, were made. Each mouse received one injection of the above formulation (5 cc./kg.) and was challenged with a Numorphan HCl injection (2 mg./kg.) at various time intervals thereafter. Results, expressed as the number of mice protected out of three, were as follows:

Time ofChallengc Test 1 Test 2 minutes 3/3 3/3 24 minutes 3/3 3/3 48 hours 2/3 2/3 72 hours 0/3 The fact that all of the mice were protected at 15 minutes shows that the suspension of the invention provides quick onset of action. At the same time the suspension provided protection to all of the mice for 24 hours and for two thirds of the mice for 48 hours. In contrast, an aqueous solution of naloxone hydrochloride protects mice for only about 5 hours.

The same formulation was also tested for duration of effect in rats. The test was subcutaneous injection for prevention of Numorphan induced loss of righting reflex. Two tests, each using four rats, were made. Each rat received one subcutaneous injection of the above formulation (1 cc./kg.) and was challenged with a subcutaneous Numorphan injection (l mg./kg.) at various time intervals thereafter. The rats were considered protected if they did not lose their righting reflex in 30 minutes after the Numorphan subcutaneous challenge. Results, expressed as the number of rats protected out of four. were as follows:

Time of Challenge Test l Test 2 15 minutes 4/4 4/4 24 hours 3/4 3/4 48 hours 2/4 3/4 72 hours l/4 25 Another suspension of the invention, containing an amount of di-naloxone pamoate equivalent to 50 mg. of naloxone hydrochloride per ml. in 2 percent aluminum monostearate in peanut oil, was tested for duration of effect in dogs. Six dogs were used. Each dog received one I.M. injection of the di- 3 naloxone pamoate suspension. The dosage was 0.1 cc./kg. for two dogs and 0.2 cc./kg. for the other four. Numorphan HCl was given at various time intervals thereafter; the dosage was 0.5 mg./kg. l.V., a prostrating dose. The following is the score system used:

0 Prostration, head drop no protection I Head weakness slight protection 2 Hind and front leg weakness moderate protection 3 Hind leg weakness only almost complete protection 4 Normal, no effect complete protection.

Results were as follows:

Antagonist Time Intervals Dog Dosage 24 48 72 96 7 l0 l4 2| NoJSex (co/kg.) hrs. hrs. hrs. hrs. days days days days l/M 0.l 4 3 0 (i/M 0.2 3 l O In a similar test on two dogs, using a suspension of the invention containing an amount of di-naloxone pamoate equivalent to 50 mg. of naloxone hydrochloride per ml. of 2 percent aluminum monostearate in sesame oil, results showed that a dosage of 0.2 cc./kg. gives almost complete protection against Numorphan after 17 days.

A suspension of the invention, containing an amount of di- [N-(cyclopropylmethyl)-7,8-dihydrol 4-hydroxynormorphinone] pamoate equivalent to 10 mg. of N-cyclopropylmethyl- 7,8-dihydro-l4-hydroxynormorphinone hydrochloride per ml., in a peanut oil gel containing 2 percent aluminum monostearate, was compared with an aqueous control solution containing 10 mg./ml. of the N-(cyclopropylmethyl)-7,8- dihydro-l4-hydroxynormorphinone hydrochloride for duration of Numorphan antagonist effect in mice. The same formulations, as well as the di-naloxone pamoate formulation described above in the rat test, were also compared for duration of Numorphan antagonist effect in rats.

In the mouse: The protocol was the same as that described above for the test of the di-naloxone pamoate suspension in mice, except that each individual animal was challenged only once with a subcutaneous injection of Numorphan (different groups of mice being challenged at the various time intervals), and groups of animals were used for each point. Results, expressed as the number of mice protected out of 10, are shown in the following table; column D shows the results for mice injected with the suspension of the invention, and column C shows the results for the mice injected with the control solution.

Time of Challenge C D minutes 10/ 10 10/10 2 hours 10/10 6 hours 6/10 24 hours 0/10 9/10 48 hours 2/10 72 hours 0/10 In the rat: The protocol was the same as that described above for the test of the di-naloxone pamoate suspension in rats, except that each individual animal was challenged only once with a subcutaneous injection of Numorphan (different groups of rats being challenged at the various time intervals), the dosage of the test or control solution was 10 mg./kg., and groups of 10 animals were used for each point, except that a group of only five animals was used for the 92 hour period. Results, expressed as the number of rats protected out of 10 (or five) are shown in the following table; column D shows the results for rats injected with the di-[N-(cyclopropylmethyl)- 7,8-dihydrol 4-hydroxynormorphinone] pamoate suspension, column C shows the results for rats injected with the control solution and column E shows the results for rats injected with the di-naloxone pamoate suspension.

Time of Challenge C D E 30 minutes 10/10 10/10 l0/l0 1 hour 10/10 6 hours 8/10 24hours0/l0 10/10 10/10 41hours- 9/10 4/10 48 hours 6/10 2/10 65 hours 1/10 0/l0 72 hours- 1/10 0/10 92 hours 0/5 What is claimed is:

1. An injectable, long-acting narcotic antagonist formulation, syringeable through a 20 gauge needle, which comprises:

A. particles of a salt selected from the group consisting of di-(N-allyl-7,8-dihydro-14-hydroxynormorphinone) pamoate and di-[N-(cyclopropyl-methyl)-7,8-dihydro-14 -hydroxynormorphinone] pamoate, the average particle size of the salt being between 5 and 50 microns, and essentially all of the particles being less than microns, thoroughly dispersed and suspended in B. a gel composed of a vegetable oil which is suitable for subcutaneous or intramuscular administration, gelled with about 0.1 to 5 percent w/v of aluminum monostearate, the concentration of the pamoate salt in the gel being equivalent to a concentration of the corresponding hydrochloride salt in the range of about 1 to about 500 mg./ml.

2. Formulation of claim 1 wherein the vegetable oil is selected from the group consisting of peanut oil, corn oil, sesame oil, and cottonseed oil.

3. Formulation of claim 2 wherein the concentration of the pamoate salt in the gel is equivalent to a concentration of the corresponding hydrochloride salt in the range of about 2 to 200 mg./ml., and the concentration of aluminum monostearate in the vegetable oil is in the range of about 1.0 to 4.0 percent w/v.

Claims (2)

  1. 2. Formulation of claim 1 wherein the vegetable oil is selected from the group consisting of peanut oil, corn oil, sesame oil, and cottonseed oil.
  2. 3. Formulation of claim 2 wherein the concentration of the pamoate salt in the gel is equivalent to a concentration of the corresponding hydrochloride salt in the range of about 2 to 200 mg./ml., and the concentration of aluminum monostearate in the vegetable oil is in the range of about 1.0 to 4.0 percent w/v.
US3676557D 1971-03-02 1971-03-02 Long-acting narcotic antagonist formulations Expired - Lifetime US3676557A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12033671A true 1971-03-02 1971-03-02

Publications (1)

Publication Number Publication Date
US3676557A true US3676557A (en) 1972-07-11

Family

ID=22389610

Family Applications (1)

Application Number Title Priority Date Filing Date
US3676557D Expired - Lifetime US3676557A (en) 1971-03-02 1971-03-02 Long-acting narcotic antagonist formulations

Country Status (1)

Country Link
US (1) US3676557A (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218454A (en) * 1977-07-08 1980-08-19 Sri International N-αMethylcyclopropylmethyl derivatives of normorphine and noroodeine, and analgesic compositions and methods employing the normorphine derivatives
US4269843A (en) * 1978-05-24 1981-05-26 Sri International N-Sec-alkyl analogs of norcodeine and normorphine and analgesic compositions and methods employing the normorphine derivatives
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
EP0137600A1 (en) * 1983-07-20 1985-04-17 Euroceltique S.A. Pharmaceutically active salts of morphine
US6228863B1 (en) 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US6254884B1 (en) 1998-02-28 2001-07-03 Lg Chemical Ltd. Somatotropin compositions mixed with vitamins
US6277384B1 (en) 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US20030073714A1 (en) * 2001-08-06 2003-04-17 Christopher Breder Opioid agonist formulations with releasable and sequestered antagonist
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US6696088B2 (en) 2000-02-08 2004-02-24 Euro-Celtique, S.A. Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US20040228924A1 (en) * 2003-04-21 2004-11-18 Benjamin Oshlack Pharmaceutical products
US20080096871A1 (en) * 2005-01-05 2008-04-24 Bush Julie K Olanzapine Pamoate Dihydrate
US7384653B2 (en) 2001-08-06 2008-06-10 Purdue Pharma L.P. Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20080167533A1 (en) * 2005-02-28 2008-07-10 Petra Leyendecker Method and Device for the Assessment of Bowel Function
US7682633B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US7943173B2 (en) 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
US8182836B2 (en) 2003-04-08 2012-05-22 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US8685444B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US8846090B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507193A (en) * 1949-05-17 1950-05-09 Bristol Lab Inc Penicillin product
US2964448A (en) * 1959-01-27 1960-12-13 Anschel Joachim Relaxin composition and process for preparing same
FR1461407A (en) * 1965-06-09 1966-02-25 Sobio Lab New pamoate amines and methods for their preparation
US3254088A (en) * 1961-03-14 1966-05-31 Lewenstein Morphine derivative
US3326896A (en) * 1964-01-24 1967-06-20 Geigy Chem Corp Embonic acid addition salts of 10, 11-dihydro-5h-dibenz[b, f]azepines
US3332950A (en) * 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507193A (en) * 1949-05-17 1950-05-09 Bristol Lab Inc Penicillin product
US2964448A (en) * 1959-01-27 1960-12-13 Anschel Joachim Relaxin composition and process for preparing same
US3254088A (en) * 1961-03-14 1966-05-31 Lewenstein Morphine derivative
US3332950A (en) * 1963-03-23 1967-07-25 Endo Lab 14-hydroxydihydronormorphinone derivatives
US3326896A (en) * 1964-01-24 1967-06-20 Geigy Chem Corp Embonic acid addition salts of 10, 11-dihydro-5h-dibenz[b, f]azepines
FR1461407A (en) * 1965-06-09 1966-02-25 Sobio Lab New pamoate amines and methods for their preparation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Coatney, Am. J. Trop. Med. Hyg. 12, 504 (1963) *
McGregor, Brit. Med. J. 695, Mar. 19, 1966 *
Thompson, Am. J. Trop. Med. Hyg. 12, 481 (1963) *
Waltz, Science, 141, 723, Aug. 1963 *

Cited By (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4218454A (en) * 1977-07-08 1980-08-19 Sri International N-αMethylcyclopropylmethyl derivatives of normorphine and noroodeine, and analgesic compositions and methods employing the normorphine derivatives
US4269843A (en) * 1978-05-24 1981-05-26 Sri International N-Sec-alkyl analogs of norcodeine and normorphine and analgesic compositions and methods employing the normorphine derivatives
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
EP0137600A1 (en) * 1983-07-20 1985-04-17 Euroceltique S.A. Pharmaceutically active salts of morphine
US6656508B2 (en) 1997-04-17 2003-12-02 Amgen Inc. Sustained-release alginate gels
US7303764B2 (en) 1997-09-30 2007-12-04 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US20040097489A1 (en) * 1997-09-30 2004-05-20 Allen Douglas J. 2-methyl-thieno-benzodiazepine formulation
US6617321B2 (en) 1997-09-30 2003-09-09 Eli Lilly And Company 2-methyl-thieno-benzodiazepine formulation
US7419686B2 (en) 1997-12-22 2008-09-02 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8936808B1 (en) 1997-12-22 2015-01-20 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US8932630B1 (en) 1997-12-22 2015-01-13 Purdue Pharma L.P Opioid agonist/antagonist combinations
US6475494B2 (en) 1997-12-22 2002-11-05 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6277384B1 (en) 1997-12-22 2001-08-21 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6696066B2 (en) 1997-12-22 2004-02-24 Euro-Celtique S.A. Opioid agonist/antagonist combinations
US6627635B2 (en) 1997-12-22 2003-09-30 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US8105631B2 (en) 1997-12-22 2012-01-31 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US20040086561A1 (en) * 1997-12-22 2004-05-06 Kaiko Robert F. Opioid agonist / antagonist combinations
US9205082B2 (en) 1997-12-22 2015-12-08 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US8673355B2 (en) 1997-12-22 2014-03-18 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US20100291203A1 (en) * 1997-12-22 2010-11-18 Purdue Pharma L.P. Opioid Agonist/Antagonist Combinations
US7749542B2 (en) 1997-12-22 2010-07-06 Purdue Pharma Lp Opioid agonist/antagonist combinations
US20080292694A1 (en) * 1997-12-22 2008-11-27 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US20050192309A1 (en) * 1997-12-22 2005-09-01 Palermo Philip J. Method of preventing abuse of opioid dosage forms
US7172767B2 (en) 1997-12-22 2007-02-06 Purdue Pharma L.P. Opioid agonist / antagonist combinations
US20070122348A1 (en) * 1997-12-22 2007-05-31 Purdue Pharma L.P. Opioid agonist/antagonist combinations
US6228863B1 (en) 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
US9474750B2 (en) 1997-12-22 2016-10-25 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US8822487B2 (en) 1997-12-22 2014-09-02 Purdue Pharma L.P. Opioid agonist/opioid antagonist/acetaminophen combinations
US6254884B1 (en) 1998-02-28 2001-07-03 Lg Chemical Ltd. Somatotropin compositions mixed with vitamins
US6696088B2 (en) 2000-02-08 2004-02-24 Euro-Celtique, S.A. Tamper-resistant oral opioid agonist formulations
US20050095291A1 (en) * 2000-02-08 2005-05-05 Benjamin Oshlack Tamper-resistant oral opioid agonist formulations
US20080306104A2 (en) * 2000-02-08 2008-12-11 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US20080311199A2 (en) * 2000-02-08 2008-12-18 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7658939B2 (en) 2000-02-08 2010-02-09 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7682632B2 (en) 2000-02-08 2010-03-23 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US9456989B2 (en) 2000-02-08 2016-10-04 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US9801828B2 (en) 2000-02-08 2017-10-31 Purdue Pharma L.P. Tamper resistant oral opioid agonist formulations
US7718192B2 (en) 2000-02-08 2010-05-18 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8586088B2 (en) 2000-02-08 2013-11-19 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US20040186121A1 (en) * 2000-02-08 2004-09-23 Benjamin Oshlack Tamper-resistant oral opioid agonist formulations
US7842311B2 (en) 2000-02-08 2010-11-30 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US7842309B2 (en) 2000-02-08 2010-11-30 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8936812B2 (en) 2000-02-08 2015-01-20 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US9278073B2 (en) 2000-02-08 2016-03-08 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US20110097404A1 (en) * 2000-02-08 2011-04-28 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US20040092542A1 (en) * 2000-02-08 2004-05-13 Benjamin Oshlack Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
US8236351B2 (en) 2000-02-08 2012-08-07 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US8357399B2 (en) 2000-02-08 2013-01-22 Purdue Pharma L.P. Tamper-resistant oral opioid agonist formulations
US9161937B2 (en) 2001-05-11 2015-10-20 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9168252B2 (en) 2001-05-11 2015-10-27 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9511066B2 (en) 2001-05-11 2016-12-06 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9056051B2 (en) 2001-05-11 2015-06-16 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US8969369B2 (en) 2001-05-11 2015-03-03 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9283216B2 (en) 2001-05-11 2016-03-15 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9480685B2 (en) 2001-05-11 2016-11-01 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9283221B2 (en) 2001-05-11 2016-03-15 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9345701B1 (en) 2001-05-11 2016-05-24 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9358230B1 (en) 2001-05-11 2016-06-07 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US9084729B2 (en) 2001-05-11 2015-07-21 Purdue Pharma L.P. Abuse-resistant controlled-release opioid dosage form
US7943173B2 (en) 2001-07-18 2011-05-17 Purdue Pharma L.P. Pharmaceutical combinations of oxycodone and naloxone
US8231901B2 (en) 2001-08-06 2012-07-31 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
US8815287B2 (en) 2001-08-06 2014-08-26 Purdue Pharma L.P. Opiod agonist formulations with releasable and sequestered antagonist
US7384653B2 (en) 2001-08-06 2008-06-10 Purdue Pharma L.P. Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030157168A1 (en) * 2001-08-06 2003-08-21 Christopher Breder Sequestered antagonist formulations
US8758825B2 (en) 2001-08-06 2014-06-24 Purdue Pharma L.P. Sequestered antagonist formulations
USRE45822E1 (en) 2001-08-06 2015-12-22 Purdue Pharma L.P. Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US9949930B2 (en) 2001-08-06 2018-04-24 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
US20030073714A1 (en) * 2001-08-06 2003-04-17 Christopher Breder Opioid agonist formulations with releasable and sequestered antagonist
US7914818B2 (en) 2001-08-06 2011-03-29 Purdue Pharma L.P. Opioid agonist formulations with releasable and sequestered antagonist
US8518443B2 (en) 2001-08-06 2013-08-27 Purdue Pharma, L.P. Opioid agonist formulations with releasable and sequestered antagonist
US8465774B2 (en) 2001-08-06 2013-06-18 Purdue Pharma L.P. Sequestered antagonist formulations
US8846091B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US9907793B2 (en) 2002-04-05 2018-03-06 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US8846090B2 (en) 2002-04-05 2014-09-30 Euro-Celtique S.A. Matrix for sustained, invariant and independent release of active compounds
US9655855B2 (en) 2002-04-05 2017-05-23 Purdue Pharma L.P. Matrix for sustained, invariant and independent release of active compounds
US9555000B2 (en) 2002-04-05 2017-01-31 Purdue Pharma L.P. Pharmaceutical preparation containing oxycodone and naloxone
US8685444B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US8685443B2 (en) 2002-09-20 2014-04-01 Alpharma Pharmaceuticals Llc Sequestering subunit and related compositions and methods
US8425933B2 (en) 2003-04-08 2013-04-23 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
US8182836B2 (en) 2003-04-08 2012-05-22 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
US8703186B2 (en) 2003-04-08 2014-04-22 Elite Laboratories, Inc. Abuse-resistant oral dosage forms and method of use thereof
US10092519B2 (en) 2003-04-21 2018-10-09 Purdue Pharma L.P. Pharmaceutical products
US20040228924A1 (en) * 2003-04-21 2004-11-18 Benjamin Oshlack Pharmaceutical products
US9149436B2 (en) 2003-04-21 2015-10-06 Purdue Pharma L.P. Pharmaceutical product comprising a sequestered agent
US7932249B2 (en) 2005-01-05 2011-04-26 Eli Lilly And Company Olanzapine pamoate dihydrate
US20080096871A1 (en) * 2005-01-05 2008-04-24 Bush Julie K Olanzapine Pamoate Dihydrate
US10258235B2 (en) 2005-02-28 2019-04-16 Purdue Pharma L.P. Method and device for the assessment of bowel function
US20080167533A1 (en) * 2005-02-28 2008-07-10 Petra Leyendecker Method and Device for the Assessment of Bowel Function
US7682634B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US7682633B2 (en) 2006-06-19 2010-03-23 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8158156B2 (en) 2006-06-19 2012-04-17 Alpharma Pharmaceuticals, Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US8877247B2 (en) 2006-06-19 2014-11-04 Alpharma Pharmaceuticals Llc Abuse-deterrent multi-layer pharmaceutical composition comprising an opioid antagonist and an opioid agonist
US8846104B2 (en) 2006-06-19 2014-09-30 Alpharma Pharmaceuticals Llc Pharmaceutical compositions for the deterrence and/or prevention of abuse
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US9820983B2 (en) 2009-03-10 2017-11-21 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US9271940B2 (en) 2009-03-10 2016-03-01 Purdue Pharma L.P. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation

Similar Documents

Publication Publication Date Title
Martin Drugs five years later: naloxone
ES2339392T3 (en) Compositions Controlled release oxycodone.
EP0602586B1 (en) Stable pharmaceutical composition of fumagillol derivatives
CA1203172A (en) Propylene glycol diester solutions of pge-type compounds
EP0236684B1 (en) Galanthamine or analogues thereof for treating alzheimer's disease
ES2415876T3 (en) Oral pharmaceutical dosage form comprising a combination of an opioid agonist and an opioid antagonist
US3870794A (en) Treatment of certain emotional disorders with nicotine compounds
US3636219A (en) Anticholinergic compositions containing certain thiazolines or imidazolines
JP4745576B2 (en) Pharmaceutical compositions
CN1093762C (en) Aqueous suspension of 9-hydroxyrisperidone fatty and esters
US4857312A (en) Dihydropyridine spray, process for its preparation and its pharmaceutical use
EP1778238B1 (en) Dihydropteridinone infusion solution having a long shelf life
Hofmann Psychotomimetic drugs
ES2120451T7 (en) Composition comprising a compound of tramadol and acetaminophen, and its use.
US5290784A (en) Aconitane derivatives used as a medication to treat addiction
Sadove et al. Study of a narcotic antagonist—n-allyl-noroxymorphone
KR960000430B1 (en) Pharmaceutical compositions stabilized against oxidation
EP0697019B1 (en) Risperidone pamoate
Woods The pharmacology of nalorphine (N-allylnormorphine)
CA1241600A (en) Pharmaceutical products providing enhanced analgesia
CA2046943C (en) Process for producing an agent with the active substance flupirtine to combat muscular tension
CA1200501A (en) Nalbuphine - narcotic analgesic composition and method of producing analgesia
ES2287629T3 (en) Drug compositions based on salts of tiotropium and salmeterol salts.
US4340596A (en) Preparations for the treatment of theileriosis and their use
EP0158532B1 (en) Use of 4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide for the manufacture of a medicament having anti-emetic activity.

Legal Events

Date Code Title Description
AS Assignment

Owner name: E.I. DU PONT DE NEMOURS AND COMPANY, 1007 MARKET S

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:ENDO LABORATORIES, INC., A CORP. OF DEL.;REEL/FRAME:004063/0107

Effective date: 19821110